Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 3;5(4):e000763. doi: 10.1136/esmoopen-2020-000763

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Response patterns. (A) Pseudoprogression: a 65-year-old man treated with SRT (6×5 Gy) to the surgical bed in April 2017, followed by four cycles of ipilimumab from April to July 2017. (B) Radionecrosis: A 57-year-old woman treated with SRT (5×5) February to March 2013, followed by four cycles of ipilimumab from February to April 2013. (C) CR: A 35-year-old woman treated with SRT (1×20 Gy) in February 2016, followed by three cycles of pembrolizumab. Gy, Grey; SRT, stereotactic radiotherapy.